#最小單位貼紙

高磷酸血症 Hyperphosphatemia
Reduction of serum phosphate in patients with end-stage renal disease (ESRD)
#仿單變更2021

Phosphate Binder
Disassociates in the upper gastrointestinal tract to lanthanum ions (La³⁺) which bind to dietary phosphate resulting in insoluble lanthanum phosphate complexes and a net decrease in serum phosphate and calcium levels

Absorption: <0.002%
Protein binding: >99%
Metabolism: Not metabolized
Half-life elimination: Plasma: 53 hours; Bone: 2-3.6 years
Excretion: Feces primarily; urine <2%

Bowel obstruction, fecal impaction, ileus

C

Consider the possibility of infant exposure when administering to a breast-feeding woman

Diarrhea, nausea, vomiting, hypocalcemia, abdominal pain
Caution: Monitor closely for GI symptoms <2021/8/18>

Administration:
1. With or immediately after meals
2. Chew thoroughly to decrease risk of serious adverse GI effects, do not swallow whole<2021/8/18>
Dosage:
1. Initial 1,500 mg daily divided; typical increases of 750 mg daily every 2 to 3 weeks are suggested as needed to reduce the serum phosphate level <6 mg/dL (1.92 mmol/L)
2. Usual dosage range: 1,500 to 3,000 mg daily; doses of up to 4,500 mg have been evaluated

No dosage adjustment necessary

Unknown (manufacturer's labeling)